

# BIOFRONTERA INC.

ISIN: US09077D2099 WKN: 09077D209 Asset Class: **Stock**

## Company

2024/08/16 22:00:00

Price  
**1.36** USD

Difference ▲ 17.24%(0.20)



## Contact Details

BIOFRONTERA INC. Tel: +1-781-245-1325  
 -- Fax: +  
 120 Presidnetial Way, Suite 330 Web: <http://www.biofrontera-us.com>  
 01801 Woburn E-mail: [info-us@biofrontera.com](mailto:info-us@biofrontera.com)

## Company Profile

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	23,075,000		43,140,000		46,421,000	
<b>Common stock capital</b>		2,000		27,000		17,000
<b>Fixed assets</b>	4,857,000		7,744,000		6,798,000	
<b>Equity capital of a company</b>		4,793,000		23,878,000		11,338,000
<b>Cash and cash equivalents</b>	1,343,000		17,208,000		24,545,000	
<b>Accrued liabilities</b>		0		0		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		18,088,000		20,894,000		13,836,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		5,051,000		6,112,000		28,045,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		4,247,000		5,264,000		28,045,000
<b>Total assets</b>	27,932,000	27,932,000	50,884,000	50,884,000	53,219,000	53,219,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	85	81	69
<b>Equity ratio</b>	17.16%	46.93%	21.30%
<b>Debt-equity ratio</b>	482.77%	113.10%	369.39%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	-0.07%	-5.26%	-0.15%

# BIOFRONTERA INC.

ISIN: US09077D2099

WKN: 09077D209

Asset Class: **Stock**

## Income statement

	2023	2022	2021
<b>Turnover</b>	34,071,000	28,674,000	24,100,000
<b>Net income</b>	-20,131,000	-640,000	-37,713,000
<b>EBIT</b>	-17,845,222	-375,087	-33,887,667
<b>Operating income before taxes</b>	-20,117,000	-608,000	-37,657,000
<b>Cash Flow</b>	-24,895,000	-16,199,000	-26,715,000
<b>Net interest income</b>	-468,000	-195,000	-344,000
<b>Research and development expenses</b>	77,000	-	-
<b>Income taxes</b>	14,000	32,000	56,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	364,039	321,503	317,212

## Board of Directors

## Members of Management Board

Beth Hoffman	Member of Board of Directors
Heikki Lanckriet	Member of Board of Directors
John Borer	Member of Board of Directors
Kevin Weber	Member of Board of Directors
Dr. Hermann Lübbert	Chairman of Managing Board
Fred Leffler	Member of Executive Committee